AU2008240379B2 - Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss - Google Patents

Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss Download PDF

Info

Publication number
AU2008240379B2
AU2008240379B2 AU2008240379A AU2008240379A AU2008240379B2 AU 2008240379 B2 AU2008240379 B2 AU 2008240379B2 AU 2008240379 A AU2008240379 A AU 2008240379A AU 2008240379 A AU2008240379 A AU 2008240379A AU 2008240379 B2 AU2008240379 B2 AU 2008240379B2
Authority
AU
Australia
Prior art keywords
agonist
treatment
progestin
product
muscle loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008240379A
Other languages
English (en)
Other versions
AU2008240379A1 (en
Inventor
Julian Clive Gilbert
Robert William Gristwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of AU2008240379A1 publication Critical patent/AU2008240379A1/en
Application granted granted Critical
Publication of AU2008240379B2 publication Critical patent/AU2008240379B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
AU2008240379A 2007-04-24 2008-04-24 Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss Ceased AU2008240379B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0707930.4 2007-04-24
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0707931.2 2007-04-24
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use
GB0710101.7 2007-05-25
PCT/GB2008/001452 WO2008129308A2 (en) 2007-04-24 2008-04-24 Drug combination and its use in the treatment of muscle loss

Publications (2)

Publication Number Publication Date
AU2008240379A1 AU2008240379A1 (en) 2008-10-30
AU2008240379B2 true AU2008240379B2 (en) 2012-10-04

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008240379A Ceased AU2008240379B2 (en) 2007-04-24 2008-04-24 Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss

Country Status (16)

Country Link
US (1) US8653052B2 (enExample)
EP (1) EP2155180B1 (enExample)
JP (1) JP5627452B2 (enExample)
KR (1) KR101546977B1 (enExample)
CN (2) CN101730547A (enExample)
AU (1) AU2008240379B2 (enExample)
BR (1) BRPI0810461A2 (enExample)
CA (1) CA2721739C (enExample)
DK (1) DK2155180T3 (enExample)
EA (1) EA018918B1 (enExample)
ES (1) ES2592289T3 (enExample)
HK (1) HK1202262A1 (enExample)
IL (1) IL201426A (enExample)
MX (1) MX2009011294A (enExample)
NZ (1) NZ580975A (enExample)
WO (1) WO2008129308A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2646012A4 (en) * 2010-11-24 2014-12-10 Neothetics Inc MONOTHERAPEUTIC FORMULATIONS OF SELECTIVE, LIPOPHILIC AND PROLONGED BETA AGONISTS AND METHODS OF COSMETIC TREATMENT OF SILHOUETTE ADPOSITY AND REINFORCEMENT
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
US11400060B2 (en) * 2020-01-13 2022-08-02 Astromedical Biotechnology, Ltd. Use of ketamine in the treatment of cachexia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006003222A1 (es) * 2004-06-29 2006-01-12 Universidad De Barcelona Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
WO2007095497A2 (en) * 2006-02-13 2007-08-23 Anaborex Inc. Compositions and methods for prevention and treatment of cachexia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149089T1 (de) 1987-09-15 1997-03-15 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen agonisten
CA2481390C (en) * 2002-04-12 2012-11-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US8080528B2 (en) * 2005-12-22 2011-12-20 The Releef Initiative Compositions and methods for treatment of cachexia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
WO2006003222A1 (es) * 2004-06-29 2006-01-12 Universidad De Barcelona Uso del formoterol en el tratamiento profiláctico y/o terapéutico del desgaste muscular y/o síndrome caquéctico, asociados a estados catabólicos de ciertas enfermedades como cáncer, sida, infecciones, diabetes y otras
WO2007095497A2 (en) * 2006-02-13 2007-08-23 Anaborex Inc. Compositions and methods for prevention and treatment of cachexia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUSQUETS, S et al. CANCER RESEARCH, 2004. Vol. 64: pages 6725-6731 *
GOMEZ, F et al. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2002. Vol.9(3): pages 583-587 *
HARCOURT, L et al. NEUROMUSCULAR DISORDERS, Feb 2007. Vol. 17, no. 1: pages 47-55 *
MANTOVANI G et al. EUROPEAN JOURNAL OF CANCER, 1997. Vol.33(4): pages 602-607 *
RYALL, J et al. BRITISH JOURNAL OF PHARMACOLOGY, 2006. Vol.147, no.6: pages 587-595 *
TOMISKA, M et al. NEOPLASMA, 2003. Vol. 50(3): pages 227-233 *

Also Published As

Publication number Publication date
EP2155180B1 (en) 2016-07-13
EP2155180A2 (en) 2010-02-24
DK2155180T3 (en) 2016-09-12
CA2721739A1 (en) 2008-10-30
MX2009011294A (es) 2010-01-29
KR101546977B1 (ko) 2015-08-24
KR20100017205A (ko) 2010-02-16
ES2592289T3 (es) 2016-11-29
WO2008129308A3 (en) 2009-12-17
IL201426A0 (en) 2010-05-31
EA018918B1 (ru) 2013-11-29
EA200970957A1 (ru) 2010-04-30
IL201426A (en) 2016-09-29
HK1202262A1 (en) 2015-09-25
US20100130456A1 (en) 2010-05-27
CA2721739C (en) 2016-08-23
JP2010525044A (ja) 2010-07-22
JP5627452B2 (ja) 2014-11-19
CN104306381A (zh) 2015-01-28
WO2008129308A2 (en) 2008-10-30
BRPI0810461A2 (pt) 2014-10-14
US8653052B2 (en) 2014-02-18
NZ580975A (en) 2012-10-26
AU2008240379A1 (en) 2008-10-30
CN101730547A (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
Farzi et al. The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour
TWI492745B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
RU2617502C2 (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
CA2721739C (en) Drug combination and its use in the treatment of muscle loss
TW200942235A (en) Dosing regimen for a selective S1P1 receptor agonist
US20240074993A1 (en) Methods of treating or preventing an attention disorder, cognitive disorder, and/or dementia associated with a neurodegenerative disorder
CA2671622C (en) Treatment of cachexia
WO2018166404A1 (zh) 雷公藤红素用于预防和/或治疗胆汁淤积性肝病以及肝纤维化的用途
CN1703244A (zh) Ppar配体和抗氧剂间的联合及其用于治疗肥胖的用途
Chen et al. Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling
JP6473152B2 (ja) がん関連悪液質を抑制するためのｈｄａｃ阻害剤
WO2008035177A2 (en) Combination of mt1 and mt2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor
HK1144555A (en) Drug combination of beta 2 agonist and a progestin for the treatment of muscle loss
Lambert Cachexia-Prolonging Life
CN1290581C (zh) 高血压症治疗药
WO2026080594A1 (en) Metopimazine and its salts as adjunct therapy with glp-1 agonists
JP2013525357A (ja) 多発性骨髄腫の治療のための組成物および方法
HK1073257A1 (en) Remedies for chronic kidney diseases
HK1073257B (en) Remedies for chronic kidney diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired